Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Kinase control prevents HIV-1 reactivation in spite of high levels of induced NF-κB activity.

Wolschendorf F, Bosque A, Shishido T, Duverger A, Jones J, Planelles V, Kutsch O.

J Virol. 2012 Apr;86(8):4548-58. doi: 10.1128/JVI.06726-11. Epub 2012 Feb 15.

2.

Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+ T cells.

Bosque A, Famiglietti M, Weyrich AS, Goulston C, Planelles V.

PLoS Pathog. 2011 Oct;7(10):e1002288. doi: 10.1371/journal.ppat.1002288. Epub 2011 Oct 6.

3.

Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model.

Shan L, Yang HC, Rabi SA, Bravo HC, Shroff NS, Irizarry RA, Zhang H, Margolick JB, Siliciano JD, Siliciano RF.

J Virol. 2011 Jun;85(11):5384-93. doi: 10.1128/JVI.02536-10. Epub 2011 Mar 23.

4.

Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation.

Allers K, Hütter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, Schneider T.

Blood. 2011 Mar 10;117(10):2791-9. doi: 10.1182/blood-2010-09-309591. Epub 2010 Dec 8.

5.

Hit-and-run stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene induction.

Wolschendorf F, Duverger A, Jones J, Wagner FH, Huff J, Benjamin WH, Saag MS, Niederweis M, Kutsch O.

J Virol. 2010 Sep;84(17):8712-20. doi: 10.1128/JVI.00523-10. Epub 2010 Jun 10.

6.

Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction.

Tyagi M, Pearson RJ, Karn J.

J Virol. 2010 Jul;84(13):6425-37. doi: 10.1128/JVI.01519-09. Epub 2010 Apr 21.

7.

Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.

Archin NM, Cheema M, Parker D, Wiegand A, Bosch RJ, Coffin JM, Eron J, Cohen M, Margolis DM.

PLoS One. 2010 Feb 23;5(2):e9390. doi: 10.1371/journal.pone.0009390.

8.

Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation.

Yang HC, Xing S, Shan L, O'Connell K, Dinoso J, Shen A, Zhou Y, Shrum CK, Han Y, Liu JO, Zhang H, Margolick JB, Siliciano RF.

J Clin Invest. 2009 Nov;119(11):3473-86. doi: 10.1172/JCI39199. Epub 2009 Oct 1.

9.

Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma.

Edelstein LC, Micheva-Viteva S, Phelan BD, Dougherty JP.

AIDS Res Hum Retroviruses. 2009 Sep;25(9):883-7. doi: 10.1089/aid.2008.0294.

10.

A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression.

Keedy KS, Archin NM, Gates AT, Espeseth A, Hazuda DJ, Margolis DM.

J Virol. 2009 May;83(10):4749-56. doi: 10.1128/JVI.02585-08. Epub 2009 Mar 11.

11.

Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid.

Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM.

AIDS Res Hum Retroviruses. 2009 Feb;25(2):207-12. doi: 10.1089/aid.2008.0191.

12.

Determinants of the establishment of human immunodeficiency virus type 1 latency.

Duverger A, Jones J, May J, Bibollet-Ruche F, Wagner FA, Cron RQ, Kutsch O.

J Virol. 2009 Apr;83(7):3078-93. doi: 10.1128/JVI.02058-08. Epub 2009 Jan 14.

13.

Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells.

Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, Martin J, Peterlin BM.

J Biol Chem. 2009 Mar 13;284(11):6782-9. doi: 10.1074/jbc.M807898200. Epub 2009 Jan 9.

14.

Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells.

Bosque A, Planelles V.

Blood. 2009 Jan 1;113(1):58-65. doi: 10.1182/blood-2008-07-168393. Epub 2008 Oct 10.

15.

Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency.

Pearson R, Kim YK, Hokello J, Lassen K, Friedman J, Tyagi M, Karn J.

J Virol. 2008 Dec;82(24):12291-303. doi: 10.1128/JVI.01383-08. Epub 2008 Oct 1.

16.

Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough.

Han Y, Lin YB, An W, Xu J, Yang HC, O'Connell K, Dordai D, Boeke JD, Siliciano JD, Siliciano RF.

Cell Host Microbe. 2008 Aug 14;4(2):134-46. doi: 10.1016/j.chom.2008.06.008.

17.

Transcriptional interference antagonizes proviral gene expression to promote HIV latency.

Lenasi T, Contreras X, Peterlin BM.

Cell Host Microbe. 2008 Aug 14;4(2):123-33. doi: 10.1016/j.chom.2008.05.016.

18.

Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.

Archin NM, Eron JJ, Palmer S, Hartmann-Duff A, Martinson JA, Wiegand A, Bandarenko N, Schmitz JL, Bosch RJ, Landay AL, Coffin JM, Margolis DM.

AIDS. 2008 Jun 19;22(10):1131-5. doi: 10.1097/QAD.0b013e3282fd6df4.

19.

Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells.

Choudhary SK, Archin NM, Margolis DM.

J Infect Dis. 2008 Apr 15;197(8):1162-70. doi: 10.1086/529525.

PMID:
18419522
20.

The receptor tyrosine kinase RON represses HIV-1 transcription by targeting RNA polymerase II processivity.

Klatt A, Zhang Z, Kalantari P, Hankey PA, Gilmour DS, Henderson AJ.

J Immunol. 2008 Feb 1;180(3):1670-7.

Supplemental Content

Support Center